Mechanism of Alzheimer type II astrocyte development in hepatic encephalopathy

Type C hepatic encephalopathy (Type C HE) is a major and complex neurological condition that occurs following chronic liver failure. The molecular basis of Type C HE remains elusive. Type C HE is characterized by mental confusion, cognitive and motor disturbances. The presence of Alzheimer type II a...

Ausführliche Beschreibung

Gespeichert in:
Bibliographische Detailangaben
Veröffentlicht in:Neurochemistry international 2024-11, Vol.180, p.105866, Article 105866
Hauptverfasser: Tong, Xiao Y., Norenberg, Michael D., Paidas, Michael J., Shamaladevi, Nagarajarao, Salgueiro, Luis, Jaszberenyi, Miklos, John, Binu, Hussain, Hussain, El hiba, Omar, Abdeljalil, El got, Bilal, El-Mansoury, Natarajan, Sampath, Romaguera, Rita, Papayan, Stanislav, Carden, Arianna K., Ramamoorthy, Rajalakshmi, Elumalai, Nila, Schally, Andrew V., Nithura, Jayakumar, Patrizio, Rebecca, Jayakumar, Arumugam R.
Format: Artikel
Sprache:eng
Schlagworte:
Online-Zugang:Volltext
Tags: Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
container_end_page
container_issue
container_start_page 105866
container_title Neurochemistry international
container_volume 180
creator Tong, Xiao Y.
Norenberg, Michael D.
Paidas, Michael J.
Shamaladevi, Nagarajarao
Salgueiro, Luis
Jaszberenyi, Miklos
John, Binu
Hussain, Hussain
El hiba, Omar
Abdeljalil, El got
Bilal, El-Mansoury
Natarajan, Sampath
Romaguera, Rita
Papayan, Stanislav
Carden, Arianna K.
Ramamoorthy, Rajalakshmi
Elumalai, Nila
Schally, Andrew V.
Nithura, Jayakumar
Patrizio, Rebecca
Jayakumar, Arumugam R.
description Type C hepatic encephalopathy (Type C HE) is a major and complex neurological condition that occurs following chronic liver failure. The molecular basis of Type C HE remains elusive. Type C HE is characterized by mental confusion, cognitive and motor disturbances. The presence of Alzheimer type II astrocytes (AT2A) is the key histopathological finding observed in Type C HE. However, nothing is currently known regarding AT2A development and its involvement in cognitive, and motor deficits in Type C HE. We, therefore, examined in rats the mechanisms by which liver failure contributes to the progression of AT2A, and its role in the development of cognitive and motor deficits in thioacetamide (TAA) model of Type C HE. We and others earlier reported increased oxidative/nitrosative stress (ONS), JNK1/2, and cMyc activation in ammonia-treated astrocyte cultures, as well as in brains from chronic liver failure. We now found increased levels of astrocytic glia maturation factor (GMF, a factor strongly implicated in neuroinflammation), as well as various inflammatory factors (IL-1β, TNF-α, IL-6, MMP-3, COX2, CXCL1, and PGE2), and reduced levels of GFAP and increased levels of aggregated nuclear protein Lamin A/C in rat brain cortex post-chronic liver failure. We also found increased levels of GMF and inflammatory factors (MMP-3, COX2, CXCL1, and PGE2) in astrocytes post-ammonia treatment in vitro. Additionally, pharmacological inhibition of upstream signaling of GMF (ONS, JNK1/2, and cMyc) or GMF inhibitors W-7 and trifluoperazine significantly reduced the levels of inflammatory factors, the number of AT2A cells, as well as the cognitive and motor deficits in TAA-treated rats. Increased levels of GMF were also identified in human post-mortem brain sections. These findings strongly suggest that increased levels of astrocytic GMF due to elevated levels of ONS, JNK1/2, and cMyc and the subsequent inflammation contribute to the development of AT2A and the consequent cognitive, and motor deficits in chronic liver failure. •Type C HE is a major neurological condition that occurs post-chronic liver failure.•Alzheimer type II astrocytes (AT2A) have been frequently observed in Type C HE.•Nothing is currently known regarding AT2A development in Type C HE.•We show the involvement of GMF and inflammatory factors in AT2A development.
doi_str_mv 10.1016/j.neuint.2024.105866
format Article
fullrecord <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_3113746336</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S0197018624001931</els_id><sourcerecordid>3113746336</sourcerecordid><originalsourceid>FETCH-LOGICAL-c241t-adc093645c6c77bd7bb585daaabc84a1f596cb53e7901ae0af048b8ac562a3bc3</originalsourceid><addsrcrecordid>eNp9kMtu2zAQRYmiQey4-YOi4LIbuaT4kjYFgiBNDLjJJl0TI2oE0dCrJB3A_frKkNNlVwPM3Dtz5xDymbMtZ1x_O2wHPPohbXOWy7mlCq0_kDUvTJ6VRsmPZM14aTLGC70iNzEeGGOmZOqarEQpdGlKuSbPP9G1MPjY07Ghd92fFn2PgabThHS3oxBTGN0pIa3xDbtx6nFI1A-0xQmSdxQHh1ML8wRSe_pErhroIt5e6ob8-vHwev-U7V8ed_d3-8zlkqcMasfmCFI57YypalNVqlA1AFSukMAbVWpXKYFzXg7IoGGyqApwSucgKic25Ouydwrj7yPGZHsfHXYdDDgeoxWcCyO1EHqWykXqwhhjwMZOwfcQTpYzeyZpD3Yhac8k7UJytn25XDhWPdb_TO_oZsH3RYDzn28eg43On2nUPqBLth79_y_8Bap4h_8</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>3113746336</pqid></control><display><type>article</type><title>Mechanism of Alzheimer type II astrocyte development in hepatic encephalopathy</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Tong, Xiao Y. ; Norenberg, Michael D. ; Paidas, Michael J. ; Shamaladevi, Nagarajarao ; Salgueiro, Luis ; Jaszberenyi, Miklos ; John, Binu ; Hussain, Hussain ; El hiba, Omar ; Abdeljalil, El got ; Bilal, El-Mansoury ; Natarajan, Sampath ; Romaguera, Rita ; Papayan, Stanislav ; Carden, Arianna K. ; Ramamoorthy, Rajalakshmi ; Elumalai, Nila ; Schally, Andrew V. ; Nithura, Jayakumar ; Patrizio, Rebecca ; Jayakumar, Arumugam R.</creator><creatorcontrib>Tong, Xiao Y. ; Norenberg, Michael D. ; Paidas, Michael J. ; Shamaladevi, Nagarajarao ; Salgueiro, Luis ; Jaszberenyi, Miklos ; John, Binu ; Hussain, Hussain ; El hiba, Omar ; Abdeljalil, El got ; Bilal, El-Mansoury ; Natarajan, Sampath ; Romaguera, Rita ; Papayan, Stanislav ; Carden, Arianna K. ; Ramamoorthy, Rajalakshmi ; Elumalai, Nila ; Schally, Andrew V. ; Nithura, Jayakumar ; Patrizio, Rebecca ; Jayakumar, Arumugam R.</creatorcontrib><description>Type C hepatic encephalopathy (Type C HE) is a major and complex neurological condition that occurs following chronic liver failure. The molecular basis of Type C HE remains elusive. Type C HE is characterized by mental confusion, cognitive and motor disturbances. The presence of Alzheimer type II astrocytes (AT2A) is the key histopathological finding observed in Type C HE. However, nothing is currently known regarding AT2A development and its involvement in cognitive, and motor deficits in Type C HE. We, therefore, examined in rats the mechanisms by which liver failure contributes to the progression of AT2A, and its role in the development of cognitive and motor deficits in thioacetamide (TAA) model of Type C HE. We and others earlier reported increased oxidative/nitrosative stress (ONS), JNK1/2, and cMyc activation in ammonia-treated astrocyte cultures, as well as in brains from chronic liver failure. We now found increased levels of astrocytic glia maturation factor (GMF, a factor strongly implicated in neuroinflammation), as well as various inflammatory factors (IL-1β, TNF-α, IL-6, MMP-3, COX2, CXCL1, and PGE2), and reduced levels of GFAP and increased levels of aggregated nuclear protein Lamin A/C in rat brain cortex post-chronic liver failure. We also found increased levels of GMF and inflammatory factors (MMP-3, COX2, CXCL1, and PGE2) in astrocytes post-ammonia treatment in vitro. Additionally, pharmacological inhibition of upstream signaling of GMF (ONS, JNK1/2, and cMyc) or GMF inhibitors W-7 and trifluoperazine significantly reduced the levels of inflammatory factors, the number of AT2A cells, as well as the cognitive and motor deficits in TAA-treated rats. Increased levels of GMF were also identified in human post-mortem brain sections. These findings strongly suggest that increased levels of astrocytic GMF due to elevated levels of ONS, JNK1/2, and cMyc and the subsequent inflammation contribute to the development of AT2A and the consequent cognitive, and motor deficits in chronic liver failure. •Type C HE is a major neurological condition that occurs post-chronic liver failure.•Alzheimer type II astrocytes (AT2A) have been frequently observed in Type C HE.•Nothing is currently known regarding AT2A development in Type C HE.•We show the involvement of GMF and inflammatory factors in AT2A development.</description><identifier>ISSN: 0197-0186</identifier><identifier>ISSN: 1872-9754</identifier><identifier>EISSN: 1872-9754</identifier><identifier>DOI: 10.1016/j.neuint.2024.105866</identifier><identifier>PMID: 39369794</identifier><language>eng</language><publisher>England: Elsevier Ltd</publisher><subject>Alzheimer Disease - metabolism ; Alzheimer Disease - pathology ; Ammonia ; Animals ; Astrocytes - metabolism ; Astrocytes - pathology ; Cognitive and motor deficits ; Glia maturation factor ; Hepatic encephalopathy ; Hepatic Encephalopathy - metabolism ; Hepatic Encephalopathy - pathology ; Inflammatory factors ; Male ; Rats ; Rats, Sprague-Dawley ; Thioacetamide - toxicity</subject><ispartof>Neurochemistry international, 2024-11, Vol.180, p.105866, Article 105866</ispartof><rights>2024 Elsevier Ltd</rights><rights>Copyright © 2024 Elsevier Ltd. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><cites>FETCH-LOGICAL-c241t-adc093645c6c77bd7bb585daaabc84a1f596cb53e7901ae0af048b8ac562a3bc3</cites><orcidid>0009-0009-2115-7860</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S0197018624001931$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3537,27901,27902,65306</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/39369794$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Tong, Xiao Y.</creatorcontrib><creatorcontrib>Norenberg, Michael D.</creatorcontrib><creatorcontrib>Paidas, Michael J.</creatorcontrib><creatorcontrib>Shamaladevi, Nagarajarao</creatorcontrib><creatorcontrib>Salgueiro, Luis</creatorcontrib><creatorcontrib>Jaszberenyi, Miklos</creatorcontrib><creatorcontrib>John, Binu</creatorcontrib><creatorcontrib>Hussain, Hussain</creatorcontrib><creatorcontrib>El hiba, Omar</creatorcontrib><creatorcontrib>Abdeljalil, El got</creatorcontrib><creatorcontrib>Bilal, El-Mansoury</creatorcontrib><creatorcontrib>Natarajan, Sampath</creatorcontrib><creatorcontrib>Romaguera, Rita</creatorcontrib><creatorcontrib>Papayan, Stanislav</creatorcontrib><creatorcontrib>Carden, Arianna K.</creatorcontrib><creatorcontrib>Ramamoorthy, Rajalakshmi</creatorcontrib><creatorcontrib>Elumalai, Nila</creatorcontrib><creatorcontrib>Schally, Andrew V.</creatorcontrib><creatorcontrib>Nithura, Jayakumar</creatorcontrib><creatorcontrib>Patrizio, Rebecca</creatorcontrib><creatorcontrib>Jayakumar, Arumugam R.</creatorcontrib><title>Mechanism of Alzheimer type II astrocyte development in hepatic encephalopathy</title><title>Neurochemistry international</title><addtitle>Neurochem Int</addtitle><description>Type C hepatic encephalopathy (Type C HE) is a major and complex neurological condition that occurs following chronic liver failure. The molecular basis of Type C HE remains elusive. Type C HE is characterized by mental confusion, cognitive and motor disturbances. The presence of Alzheimer type II astrocytes (AT2A) is the key histopathological finding observed in Type C HE. However, nothing is currently known regarding AT2A development and its involvement in cognitive, and motor deficits in Type C HE. We, therefore, examined in rats the mechanisms by which liver failure contributes to the progression of AT2A, and its role in the development of cognitive and motor deficits in thioacetamide (TAA) model of Type C HE. We and others earlier reported increased oxidative/nitrosative stress (ONS), JNK1/2, and cMyc activation in ammonia-treated astrocyte cultures, as well as in brains from chronic liver failure. We now found increased levels of astrocytic glia maturation factor (GMF, a factor strongly implicated in neuroinflammation), as well as various inflammatory factors (IL-1β, TNF-α, IL-6, MMP-3, COX2, CXCL1, and PGE2), and reduced levels of GFAP and increased levels of aggregated nuclear protein Lamin A/C in rat brain cortex post-chronic liver failure. We also found increased levels of GMF and inflammatory factors (MMP-3, COX2, CXCL1, and PGE2) in astrocytes post-ammonia treatment in vitro. Additionally, pharmacological inhibition of upstream signaling of GMF (ONS, JNK1/2, and cMyc) or GMF inhibitors W-7 and trifluoperazine significantly reduced the levels of inflammatory factors, the number of AT2A cells, as well as the cognitive and motor deficits in TAA-treated rats. Increased levels of GMF were also identified in human post-mortem brain sections. These findings strongly suggest that increased levels of astrocytic GMF due to elevated levels of ONS, JNK1/2, and cMyc and the subsequent inflammation contribute to the development of AT2A and the consequent cognitive, and motor deficits in chronic liver failure. •Type C HE is a major neurological condition that occurs post-chronic liver failure.•Alzheimer type II astrocytes (AT2A) have been frequently observed in Type C HE.•Nothing is currently known regarding AT2A development in Type C HE.•We show the involvement of GMF and inflammatory factors in AT2A development.</description><subject>Alzheimer Disease - metabolism</subject><subject>Alzheimer Disease - pathology</subject><subject>Ammonia</subject><subject>Animals</subject><subject>Astrocytes - metabolism</subject><subject>Astrocytes - pathology</subject><subject>Cognitive and motor deficits</subject><subject>Glia maturation factor</subject><subject>Hepatic encephalopathy</subject><subject>Hepatic Encephalopathy - metabolism</subject><subject>Hepatic Encephalopathy - pathology</subject><subject>Inflammatory factors</subject><subject>Male</subject><subject>Rats</subject><subject>Rats, Sprague-Dawley</subject><subject>Thioacetamide - toxicity</subject><issn>0197-0186</issn><issn>1872-9754</issn><issn>1872-9754</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2024</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNp9kMtu2zAQRYmiQey4-YOi4LIbuaT4kjYFgiBNDLjJJl0TI2oE0dCrJB3A_frKkNNlVwPM3Dtz5xDymbMtZ1x_O2wHPPohbXOWy7mlCq0_kDUvTJ6VRsmPZM14aTLGC70iNzEeGGOmZOqarEQpdGlKuSbPP9G1MPjY07Ghd92fFn2PgabThHS3oxBTGN0pIa3xDbtx6nFI1A-0xQmSdxQHh1ML8wRSe_pErhroIt5e6ob8-vHwev-U7V8ed_d3-8zlkqcMasfmCFI57YypalNVqlA1AFSukMAbVWpXKYFzXg7IoGGyqApwSucgKic25Ouydwrj7yPGZHsfHXYdDDgeoxWcCyO1EHqWykXqwhhjwMZOwfcQTpYzeyZpD3Yhac8k7UJytn25XDhWPdb_TO_oZsH3RYDzn28eg43On2nUPqBLth79_y_8Bap4h_8</recordid><startdate>202411</startdate><enddate>202411</enddate><creator>Tong, Xiao Y.</creator><creator>Norenberg, Michael D.</creator><creator>Paidas, Michael J.</creator><creator>Shamaladevi, Nagarajarao</creator><creator>Salgueiro, Luis</creator><creator>Jaszberenyi, Miklos</creator><creator>John, Binu</creator><creator>Hussain, Hussain</creator><creator>El hiba, Omar</creator><creator>Abdeljalil, El got</creator><creator>Bilal, El-Mansoury</creator><creator>Natarajan, Sampath</creator><creator>Romaguera, Rita</creator><creator>Papayan, Stanislav</creator><creator>Carden, Arianna K.</creator><creator>Ramamoorthy, Rajalakshmi</creator><creator>Elumalai, Nila</creator><creator>Schally, Andrew V.</creator><creator>Nithura, Jayakumar</creator><creator>Patrizio, Rebecca</creator><creator>Jayakumar, Arumugam R.</creator><general>Elsevier Ltd</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0009-0009-2115-7860</orcidid></search><sort><creationdate>202411</creationdate><title>Mechanism of Alzheimer type II astrocyte development in hepatic encephalopathy</title><author>Tong, Xiao Y. ; Norenberg, Michael D. ; Paidas, Michael J. ; Shamaladevi, Nagarajarao ; Salgueiro, Luis ; Jaszberenyi, Miklos ; John, Binu ; Hussain, Hussain ; El hiba, Omar ; Abdeljalil, El got ; Bilal, El-Mansoury ; Natarajan, Sampath ; Romaguera, Rita ; Papayan, Stanislav ; Carden, Arianna K. ; Ramamoorthy, Rajalakshmi ; Elumalai, Nila ; Schally, Andrew V. ; Nithura, Jayakumar ; Patrizio, Rebecca ; Jayakumar, Arumugam R.</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c241t-adc093645c6c77bd7bb585daaabc84a1f596cb53e7901ae0af048b8ac562a3bc3</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2024</creationdate><topic>Alzheimer Disease - metabolism</topic><topic>Alzheimer Disease - pathology</topic><topic>Ammonia</topic><topic>Animals</topic><topic>Astrocytes - metabolism</topic><topic>Astrocytes - pathology</topic><topic>Cognitive and motor deficits</topic><topic>Glia maturation factor</topic><topic>Hepatic encephalopathy</topic><topic>Hepatic Encephalopathy - metabolism</topic><topic>Hepatic Encephalopathy - pathology</topic><topic>Inflammatory factors</topic><topic>Male</topic><topic>Rats</topic><topic>Rats, Sprague-Dawley</topic><topic>Thioacetamide - toxicity</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Tong, Xiao Y.</creatorcontrib><creatorcontrib>Norenberg, Michael D.</creatorcontrib><creatorcontrib>Paidas, Michael J.</creatorcontrib><creatorcontrib>Shamaladevi, Nagarajarao</creatorcontrib><creatorcontrib>Salgueiro, Luis</creatorcontrib><creatorcontrib>Jaszberenyi, Miklos</creatorcontrib><creatorcontrib>John, Binu</creatorcontrib><creatorcontrib>Hussain, Hussain</creatorcontrib><creatorcontrib>El hiba, Omar</creatorcontrib><creatorcontrib>Abdeljalil, El got</creatorcontrib><creatorcontrib>Bilal, El-Mansoury</creatorcontrib><creatorcontrib>Natarajan, Sampath</creatorcontrib><creatorcontrib>Romaguera, Rita</creatorcontrib><creatorcontrib>Papayan, Stanislav</creatorcontrib><creatorcontrib>Carden, Arianna K.</creatorcontrib><creatorcontrib>Ramamoorthy, Rajalakshmi</creatorcontrib><creatorcontrib>Elumalai, Nila</creatorcontrib><creatorcontrib>Schally, Andrew V.</creatorcontrib><creatorcontrib>Nithura, Jayakumar</creatorcontrib><creatorcontrib>Patrizio, Rebecca</creatorcontrib><creatorcontrib>Jayakumar, Arumugam R.</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Neurochemistry international</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Tong, Xiao Y.</au><au>Norenberg, Michael D.</au><au>Paidas, Michael J.</au><au>Shamaladevi, Nagarajarao</au><au>Salgueiro, Luis</au><au>Jaszberenyi, Miklos</au><au>John, Binu</au><au>Hussain, Hussain</au><au>El hiba, Omar</au><au>Abdeljalil, El got</au><au>Bilal, El-Mansoury</au><au>Natarajan, Sampath</au><au>Romaguera, Rita</au><au>Papayan, Stanislav</au><au>Carden, Arianna K.</au><au>Ramamoorthy, Rajalakshmi</au><au>Elumalai, Nila</au><au>Schally, Andrew V.</au><au>Nithura, Jayakumar</au><au>Patrizio, Rebecca</au><au>Jayakumar, Arumugam R.</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Mechanism of Alzheimer type II astrocyte development in hepatic encephalopathy</atitle><jtitle>Neurochemistry international</jtitle><addtitle>Neurochem Int</addtitle><date>2024-11</date><risdate>2024</risdate><volume>180</volume><spage>105866</spage><pages>105866-</pages><artnum>105866</artnum><issn>0197-0186</issn><issn>1872-9754</issn><eissn>1872-9754</eissn><abstract>Type C hepatic encephalopathy (Type C HE) is a major and complex neurological condition that occurs following chronic liver failure. The molecular basis of Type C HE remains elusive. Type C HE is characterized by mental confusion, cognitive and motor disturbances. The presence of Alzheimer type II astrocytes (AT2A) is the key histopathological finding observed in Type C HE. However, nothing is currently known regarding AT2A development and its involvement in cognitive, and motor deficits in Type C HE. We, therefore, examined in rats the mechanisms by which liver failure contributes to the progression of AT2A, and its role in the development of cognitive and motor deficits in thioacetamide (TAA) model of Type C HE. We and others earlier reported increased oxidative/nitrosative stress (ONS), JNK1/2, and cMyc activation in ammonia-treated astrocyte cultures, as well as in brains from chronic liver failure. We now found increased levels of astrocytic glia maturation factor (GMF, a factor strongly implicated in neuroinflammation), as well as various inflammatory factors (IL-1β, TNF-α, IL-6, MMP-3, COX2, CXCL1, and PGE2), and reduced levels of GFAP and increased levels of aggregated nuclear protein Lamin A/C in rat brain cortex post-chronic liver failure. We also found increased levels of GMF and inflammatory factors (MMP-3, COX2, CXCL1, and PGE2) in astrocytes post-ammonia treatment in vitro. Additionally, pharmacological inhibition of upstream signaling of GMF (ONS, JNK1/2, and cMyc) or GMF inhibitors W-7 and trifluoperazine significantly reduced the levels of inflammatory factors, the number of AT2A cells, as well as the cognitive and motor deficits in TAA-treated rats. Increased levels of GMF were also identified in human post-mortem brain sections. These findings strongly suggest that increased levels of astrocytic GMF due to elevated levels of ONS, JNK1/2, and cMyc and the subsequent inflammation contribute to the development of AT2A and the consequent cognitive, and motor deficits in chronic liver failure. •Type C HE is a major neurological condition that occurs post-chronic liver failure.•Alzheimer type II astrocytes (AT2A) have been frequently observed in Type C HE.•Nothing is currently known regarding AT2A development in Type C HE.•We show the involvement of GMF and inflammatory factors in AT2A development.</abstract><cop>England</cop><pub>Elsevier Ltd</pub><pmid>39369794</pmid><doi>10.1016/j.neuint.2024.105866</doi><orcidid>https://orcid.org/0009-0009-2115-7860</orcidid></addata></record>
fulltext fulltext
identifier ISSN: 0197-0186
ispartof Neurochemistry international, 2024-11, Vol.180, p.105866, Article 105866
issn 0197-0186
1872-9754
1872-9754
language eng
recordid cdi_proquest_miscellaneous_3113746336
source MEDLINE; Elsevier ScienceDirect Journals
subjects Alzheimer Disease - metabolism
Alzheimer Disease - pathology
Ammonia
Animals
Astrocytes - metabolism
Astrocytes - pathology
Cognitive and motor deficits
Glia maturation factor
Hepatic encephalopathy
Hepatic Encephalopathy - metabolism
Hepatic Encephalopathy - pathology
Inflammatory factors
Male
Rats
Rats, Sprague-Dawley
Thioacetamide - toxicity
title Mechanism of Alzheimer type II astrocyte development in hepatic encephalopathy
url https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-02-06T14%3A07%3A53IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Mechanism%20of%20Alzheimer%20type%20II%20astrocyte%20development%20in%20hepatic%20encephalopathy&rft.jtitle=Neurochemistry%20international&rft.au=Tong,%20Xiao%20Y.&rft.date=2024-11&rft.volume=180&rft.spage=105866&rft.pages=105866-&rft.artnum=105866&rft.issn=0197-0186&rft.eissn=1872-9754&rft_id=info:doi/10.1016/j.neuint.2024.105866&rft_dat=%3Cproquest_cross%3E3113746336%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=3113746336&rft_id=info:pmid/39369794&rft_els_id=S0197018624001931&rfr_iscdi=true